Jerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.
Jerald P. Radich, MD, member, Clinical Research Division, Kurt Enslein Endowed Chair, Fred Hutchinson Cancer Research Center, and professor, University of Washington School of Medicine, discusses how minimal residual disease (MRD) is measured in hematologic malignancies.
In general, MRD can be measured with flow cytometry, which is a technique that measures aberrant antigen presentation on the cells. The sensitivity, however, with this technique is usually between 1 leukemia cell in 1,000 to 1 in, maybe, 104, Radich says.
Another approach is to use polymerase chain reaction (PCR)–based detection, which looks at either translocations or point mutations, Radich says. Next-generation sequencing is another approach for using a more wholesome approach at both the translocations and point mutations in 1 assay, although this approach sugars a little bit from sensitivity and cost issues.
New methods such as single-cell genomics are now underway to understand the complexity of clonal evolution and how a Darwinian selection paves the way for MRD in relapsed patients.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More